[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"MetroHealth Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":404},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,41,72,97,124,147,170,202,224,246,271,309,326,350,378],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100637843","replacing-gas-stoves-with-portable-electric-appliances-to-improve-indoor-air-quality-and-asthma-control-100637843",false,"NCT07603206","Replacing Gas Stoves With Portable Electric Appliances to Improve Indoor Air Quality and Asthma Control","Inclusion Criteria:\n\n* Currently use gas stove for cooking or baking at least three times a week\n* Poorly controlled asthma as defined by an Asthma Control Questionnaire score of 1.5 or larger\n\nExclusion Criteria:\n\n* Impaired decision making capacity\n* Pregnancy","ALL","18 Years",{"count":18,"type":19},20,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goals of this study are to determine if replacing gas stoves with portable electric hot plates and electric toaster ovens will improve indoor air quality and asthma control. Researchers will enroll participants with poorly controlled asthma and provide them with hot plates and toaster ovens to use instead of gas stoves. Researchers will measure indoor air quality about 1-2 weeks before and about 2-3 months after providing portable appliances. Participants will answer questions about their asthma symptoms and take lung function tests about 1-2 weeks before and about 2-3 months after using portable appliances.",[25],"Asthma Control",[27,28],"asthma","indoor air quality","NOT_YET_RECRUITING","2026-05-19",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":19},"2026-06",{"date":37,"type":19},"2029-05",{"name":39,"class":40},"MetroHealth Medical Center","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100627698","ai-guided-prediction-and-treatment-of-cardiac-arrest-100627698","NCT07452016","AI-guided Prediction and Treatment of Cardiac Arrest","Improving Cardiac Arrest Outcomes Using Artificial Intelligence Guided Precision Treatments","Inclusion Criteria:\n\n* Adult (18 years of age or older) EMS providers (Simulation trial)\n* Adult (18 years of age or older) patients have attempted resuscitation from out-of-hospital SCA of any etiology (Clinical trail)\n\nExclusion Criteria:\n\n* Non-English-speaking providers\n* Providers who do not care for cardiac arrest patients\n* Prisoners\n* Pediatric patients under age of 18\n* DNR\u002FDNI\n* No resuscitation attempted (declared deceased in field by EMS)",true,{"count":50,"type":19},68,[22],"Sudden cardiac arrest is a major health problem, and most people don't survive. One big reason is that even if resuscitation is successful, people commonly have recurrent cardiac arrests (rearrest). Right now, it is not possible to accurately predict a rearrest or prevent it. The investigators have developed a machine learning device that uses the heart tracing (ECG) to predict when and why a rearrest occurs. The investigators plan to test if it will accurately and effectively help EMS providers predict rearrest and provide timely treatment to increase survival after cardiac arrest. To determine if this machine learning device will work in the real world, the investigators need to find out if there are barriers to using it, and whether EMS providers will think it is useful and will help them improve the care of patients who have a cardiac arrest. The investigators will first test the device in live simulated cardiac arrest scenarios to see if the providers can use it and if they find the device potentially valuable in taking care of patients. In a second study, the investigators will test how accurate the device is in predicting if a cardiac arrest will happen again in patients who have just been brought back to life after a cardiac arrest. EMS providers will attach the device, but it will only work in the background. EMS will take care of patients as they normally would, without using or knowing what the device says. To see if the device is accurate at predicting another cardiac arrest, the investigators will analyze the results offline, and compare what the device says to what actually happens to the patient. By comparing what the device predicts to what actually happens, the investigators can see how well it predicts another cardiac arrest and estimate how it might improve treatment of patients.",[54],"Sudden Cardiac Arrest",[56,57,58,59,60,61,62],"cardiac arrest","sudden cardiac death","machine learning","rearrest","ventricular fibrillation","ventricular tachycardia","pulseless electrical activity","2026-03-12",{"date":65,"type":33},"2026-03-16",{"date":67,"type":19},"2026-08",{"date":69,"type":19},"2029-06",{"name":39,"class":40},1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":20,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":71},"100572496","multimodal-enriched-environment-for-rehabilitation-in-chronic-traumatic-brain-injury-100572496","NCT06734026","Multimodal, Enriched Environment for Rehabilitation in Chronic Traumatic Brain Injury","Multimodal, Enriched Environment for Rehabilitation","Inclusion Criteria:\n\n* moderate to severe neurological diagnosis as diagnosed by a clinician,\n* ability to comprehend multi step instructions,\n* ability to independently balance with weight support,\n* physical deficits resulting in need for additional functional goals,\n* ability to endure 2 hours of weight-supported standing,\n* ability to provide informed consent,\n* basic communication ability,\n* currently discharged from therapy,\n* \\>3 months post-injury,\n* \\>18 years of age at time of enrollment\n\nExclusion Criteria:\n\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Non-English speaking\n* Pregnant women\n* Prisoners\n* Medical instability\n* Other neurological conditions\n* Severe problems with maintaining follow-up expected (such as, but not limited to history of substance abuse, homelessness\u002Fincarceration, dementia and psychotic disorders)",{"count":18,"type":19},[22],"The goal of this study is to learn if a enhanced environment (Metro Café) with multi model approach (an approach that combines several therapies) in chronic traumatic brain injury improves outcomes of recovery better than traditional therapy. The main questions it aims to answer are:\n\n* Determine the amount of therapy dosage (speech, cognition, arm and leg movements) obtained during the Metro Café therapy session.\n* Evaluate the connection between environmental enrichment dosage (the Metro Café) and clinical outcome scores.\n\nResearchers will compare Metro Café Treatment to those who do not receive this treatment to see if better improvements in function after a traumatic brain injury are seen in the Metro Café Treatment Participants will train in the Metro Cafe during the 2-month gap between assessments, for a total of 18 training sessions, each up to 2 hours, 3 times per week. Participants will greet and serve customers drinks and snacks, maintain food supplies at the counters and performs housekeeping tasks with advice and assistance from a supervising researcher as needed,",[83],"Traumatic Brain Injury (TBI) Patients",[85,86,87],"TBI","Brain injury","Traumatic Brain Injury","RECRUITING","2026-02-27",{"date":91,"type":33},"2026-03-03",{"date":93,"type":33},"2025-04-08",{"date":95,"type":19},"2029-01-15",{"name":39,"class":40},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":20,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100627334","the-improving-sleep-in-african-american-couples-study-isaac-100627334","NCT07447284","The Improving Sleep in African American Couples Study (ISAAC)","The Improving Sleep in African American Couples (ISAAC) Study","ISAAC","Inclusion Criteria - Patient:\n\n* Moderate or severe OSA (Apnea hypopnea index ≥ 15 events\u002Fhour)\n* Age ≥ 30 years\n* Bed partner for ≥ last 6 months who is willing to participate\n* English proficient\n\nInclusion Criteria - Bed Partner\n\n* Bed partner for ≥ 6 months and willing to participate\n* English proficient\n\nExclusion Criteria - Patient:\n\n* Terminal illness\n* Neurocognitive disorder that prevents informed consent\n* Unstable housing\n* Need for other forms of positive airway pressure (BPAP or VPAP)\n* Pregnancy","30 Years",{"count":107,"type":19},440,[22],"The goal of this randomized study is to compare a combined behavioral intervention (remote tele-monitoring and feedback, virtual cognitive behavioral couple therapy, and couple-oriented peer support) on continuous positive airway pressure (CPAP) adherence, quality of sleep, functional status, and quality of life among patients with obstructive sleep apnea (OSA) and their bed partners.",[111],"Obstructive Sleep Apnea (OSA)",[113,114,115],"Sleep Apnea Syndromes\u002FTherapy","Continuous Positive Airway Pressure","Couples Therapy","2026-02-26",{"date":91,"type":33},{"date":119,"type":19},"2026-03-01",{"date":121,"type":19},"2028-07",{"name":39,"class":40},2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":20,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":71},"100563098","restoration-of-hand-function-in-cervical-sci-100563098","NCT06611748","Restoration of Hand Function in Cervical SCI","Evaluation of a Simple Neuroprosthesis for Restoration of Hand Function in Cervical Spinal Cord Injury","KeyGrip","Inclusion Criteria:\n\n* Male or female adults 18 years of age or older;\n* Cervical spinal cord injury as defined by: a) International Standard for Neurological Classification of Spinal Cord Injury motor level of C1 through C7; and b) American Spinal Injury Association Impairment Scale (AIS) grade A, B, or C;\n* Six months or more post-injury (neurostability);\n* Neurologically stable following any nerve transfers affecting the upper extremity (typically, one-year post-surgery);\n* Musculoskeletally and neurologically stable following any tendon transfers affecting the upper extremity (typically 6 months post-surgery).\n* Peripheral nerve innervation to upper extremity muscles, including Grade 3\u002F5 or higher Stimulated Manual Muscle Testin at least two of the muscles in one arm:\n* Good proximal voluntary upper extremity strength as defined by biceps\u002F brachialis \u002F brachioradialis strength of 2\u002F5 or higher on Manual Muscle Testing the side intended for implantation;\n* Medically stable; and\n* Able to understand and provide informed consent;\n\nExclusion Criteria:\n\n* Other neurological conditions (Multiple Sclerosis, diabetes with peripheral nerve involvement);\n* Associated peripheral nerve \u002F brachial plexus injury;\n* Progressive Spinal Cord Injury;\n* Active implantable medical device (AIMD) such as a pacemaker or defibrillator;\n* Active untreated infection such as urinary tract infection or pneumonia;\n* Active pressure injury;\n* History of coagulopathy, HIV, cardiopulmonary disease, bradycardia, poorly controlled autonomic dysreflexia, or chronic obstructive pulmonary disease that would preclude safe participation in the trial as determined by the investigator;\n* Unhealed fractures that prevent functional use of arm;\n* Extensive upper extremity denervation (fewer than two excitable hand muscles);\n* Involvement in other ongoing clinical studies that exclude concurrent involvement in this study;\n* Currently pregnant (neuroprosthesis implantation delayed until no longer pregnant based on self-report); Urine or serum testing will happen during the pre-surgery evaluation.\n* Presence of disease that might interfere with participant safety, compliance, or evaluation of the condition under study;\n* Other significant medical findings that, in the opinion of the investigator, preclude safe participation in the trial",{"count":18,"type":19},[22],"The purpose of this study is to evaluate a new method of restoring hand function to people with spinal cord injury. Current methods to restore hand function include tendon transfers and nerve transfers. This study will evaluate the grasp strength that can be achieved with a small, implantable stimulator.\n\nKeyGrip is an investigational device that works by activating paralyzed muscles with low levels of electrical current. The word \"investigational\" means the study device is still being tested in research studies and is not approved by the U.S. Food and Drug Administration (FDA) for the use being studied.\n\nHypothesis. The study is designed to explore the feasibility of this approach; no hypothesis is planned at this stage",[136],"Spinal Cord Injury Cervical",[138],"Cervical Spinal Cord Injury (SCI)","2026-02-20",{"date":141,"type":33},"2026-02-24",{"date":143,"type":33},"2025-01-01",{"date":145,"type":19},"2030-11",{"name":39,"class":40},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":15,"minAge":154,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":20,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":71},"100505620","grasp-release-assessment-of-a-networked-neuroprosthesis-device-100505620","NCT05863754","Grasp-Release Assessment of a Networked Neuroprosthesis Device","GRANND","Inclusion Criteria:\n\n* Male or female, age \\> 16 years.\n* Cervical level spinal cord injury, as defined by:\n\n  1. International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) motor level of C1 through C7 and\n  2. American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade A, B, or C;\n* Six months or more post-injury (neurostability);\n* Neurologically stable following any nerve transfers affecting the upper extremity (typically, one year post surgery);\n* Musculoskeletally and neurologically stable following any tendon transfers affecting the upper extremity (typically, 6-months).\n* Peripheral nerve innervation to upper extremity muscles, including a grade 3\u002F5 or higher Stimulated Manual Muscle Test (SMMT) strength in at least two of the following muscles in one arm:\n\n  1. Adductor Pollicus, Abductor Pollicus Brevis (AbPB), Flexor Pollicus Longus (FPL), Extensor Pollicus Longus (EPL)\u002FExtensor Pollicus Brevis (EPB), Extensor Digitorum Communis (EDC), Flexor Digitorum Superficialis (FDS), Flexor Digitorum Profundus (FDP), Pronator Quadratus (PQ), Extensor Carpi Ulnaris (ECU), Extensor Carpi Radialis Brevis (ECRB), Extensor Carpi Radialis Longus (ECRL), Flexor Carpi Ulnaris (FCU), Flexor Carpi Radialis (FCR), First Dorsal Interosseous(1DI), triceps,\n  2. At least two of the grade 3\u002F5 or higher excitable muscles must also have grade 2\u002F5 or lower voluntary strength;\n* Good proximal upper extremity strength as defined by biceps\u002Fbrachialis\u002Fbrachioradialis strength of 2\u002F5 or higher on Manual Muscle Test on the side intended for implantation;\n* Medically stable;\n* Able to understand and provide informed consent.\n\nExclusion Criteria:\n\n* Other neurological conditions (MS(multiple Sclerosis), diabetes with peripheral nerve involvement); Associated peripheral nerve \u002F brachial plexus injury\n* Progressive SCI;\n* Co-existing cervical spine pathology (syrinx, unstable segment)\n* Active implantable medical device (AIMD) such as a pacemaker or defibrillator;\n* Active untreated infection such as pressure injury, urinary tract infection, pneumonia;\n* History of coagulopathy, HIV, cardiopulmonary disease, bradycardia, poorly controlled autonomic dysreflexia, or chronic obstructive pulmonary disease that would preclude safe participation in the trial as determined by the investigator;\n* Unhealed fractures that prevent functional use of arm;\n* Extensive upper extremity denervation (fewer than two excitable hand muscles);\n* Involvement in other ongoing clinical studies that exclude concurrent involvement in this study;\n* Disorder or condition that requires MRI monitoring;\n* Mechanical ventilator dependency;\n* Currently pregnant (neuroprosthesis implantation delayed until no longer pregnant);\n* Presence of disease that might interfere with participant safety, compliance, or evaluation of the condition under study;\n* Other significant medical findings that, in the opinion of the investigator, preclude safe participation in the trial.","16 Years",{"count":156,"type":19},13,[22],"The overall objective of this trial is to characterize the safety and effectiveness of the Networked Neuroprosthesis Device - Upper Extremity (NP-UE) in individuals living with cervical SCI.",[160,161,136],"Spinal Cord Injury at C5-C7 Level","Spinal Cord Injuries","2025-12-17",{"date":164,"type":33},"2025-12-19",{"date":166,"type":33},"2022-01-23",{"date":168,"type":19},"2028-12-01",{"name":39,"class":40},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":20,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":71},"100580395","at-home-genital-nerve-stimulation-for-sci-bowel-100580395","NCT06836739","At-Home Genital Nerve Stimulation for SCI Bowel","At-Home Feasibility Trial of Genital Nerve Stimulation to Modulate Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury","Inclusion Criteria:\n\n1. Traumatic SCI.\n2. Minimum of 6 months' post-injury.\n3. Aged 18 years and older.\n4. Neurological level of injury T12 or higher and AIS grade A-D, as defined by the ISNCSCI.\n5. Score of 14 or higher on the ISCI BF BDS v2.1.\n6. Response to genital nerve stimulation able to be elicited upon screening.\n7. Able to understand and provide informed consent.\n\nExclusion Criteria:\n\n1. Currently enrolled in another functional electrical stimulation (FES) research trial.\n2. Females who are pregnant or planning to become pregnant in the duration of the trial (identified by self-report).\n3. Presence of a cardiac pacemaker, implanted defibrillator, or other implanted functional electrical stimulation device if, upon clinical evaluation, it may have an interaction with GNS.\n4. In the judgment of the PI and Co-Investigators, presence of medical complications that may interfere with the execution of the study.",{"count":178,"type":19},12,[22],"The purpose of this study is to test whether electrical stimulation of the skin in the pelvic area (near the genitals) can reduce the reflexes that cause bowel accidents in people with spinal cord injuries. Current bowel treatments either involve diet and medications or surgery. This study will evaluate whether electrical stimulation can be an alternate option for bowel management.\n\nResearchers will:\n\n* Use an FDA approved Transcutaneous Electrical Nerve Stimulation (TENS) device off-label\n* Compare a target stimulation level to a placebo stimulation level\n\nParticipants will:\n\n* Use electrical stimulation on the skin in the pelvic area for 6-8 hours each day for 4 weeks at home\n* Visit the research center 3 times to participate in exams and answer questions\n* Keep a daily diary of their bowel symptoms and stimulation times",[182],"Spinal Cord Injury",[184,185,186,187,188,189,190,191,192,193],"fecal incontinence","neurogenic bowel","tetraplegia","paraplegia","paralysis","electrical stimulation","neuromodulation","bowel","feasibility","anorectal manometry","2025-11-24",{"date":196,"type":33},"2025-12-02",{"date":198,"type":33},"2025-03-01",{"date":200,"type":19},"2026-09-30",{"name":39,"class":40},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":20,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":71},"100487417","acute-genital-nerve-stimulation-for-neurogenic-bowel-dysfunction-in-individuals-living-with-spinal-cord-injury-100487417","NCT05626816","Acute Genital Nerve Stimulation for Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury","Short-term Genital Nerve Stimulation to Modulate Anorectal Reflex Activity in Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury","Inclusion Criteria:\n\n* Traumatic SCI\n* Minimum 6 months post-injury\n* Aged 18 years or older\n* Neurological level of injury T12 or higher AIS grade A-D defined by ISNCSCI\n* Response to genital nerve stimulation upon screening\n* Able to understand and provide informed consent\n\nExclusion Criteria:\n\n* Currently enrolled in another functional electrical stimulation (FES) research trial\n* Females who are pregnant or planning to become pregnant during the trial\n* Presence of cardiac pacemaker, implanted defibrillator or other implanted FES device if, upon clinical exam, it may have an interaction with GNS.\n* In the judgement of the PI or Co-Investigators, presence of medical complications that may interfere with the execution of the study.",{"count":210,"type":19},52,[22],"Bowel issues occur in nearly all people after spinal cord injury (SCI) and one major complication is fecal incontinence (accidents). This complication has been repeatedly highlighted by people living with SCI as particularly life-limiting and in need of more options for interventions. This study will test the effect of genital nerve stimulation (GNS), with non-invasive electrodes, on the activity of the anus and rectum of persons after SCI. Recording anorectal manometry (ARM) endpoints tells us the function of those tissues and our study design (ARM without stim, ARM with stim, ARM without stim) will allow us to conclude the GNS effect and whether it is likely to reduce fecal incontinence. The study will also collect medical, demographic, and bowel related functional information. The combination of all of these data should help predict who will respond to stimulation, what will happen when stimulation is applied, and if that stimulation is likely to provide an improvement in fecal continence for people living with SCI.",[214],"Fecal Incontinence",[191,216,189,193,217,186,187,188],"spinal cord injury","incontinence",{"date":196,"type":33},{"date":220,"type":33},"2023-03-21",{"date":222,"type":19},"2025-12-31",{"name":39,"class":40},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":20,"phases":232,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":71},"100462541","phase-4-feasibility-of-early-gabapentin-as-an-intervention-for-neurorecovery-100462541","NCT05302999","Feasibility of Early Gabapentin as an Intervention for Neurorecovery","Inclusion Criteria:\n\n1. Traumatic SCI;\n2. All levels of SCI;\n3. All severities of SCI, AIS A-D;\n4. Age 18 years and older.\n5. Agree to participate and start study drug within 120 hours' post-injury.\n6. Adequate cognition and communication to provide informed consent\n\nExclusion Criteria:\n\n1. Presence of moderate\u002Fsevere traumatic brain injury (TBI) as defined by Glasgow Coma Score (GCS) \\\u003C 13 at 120 hours' post-injury.\n2. Documented use of gabapentinoids at the time of injury.",{"count":231,"type":19},42,[233],"PHASE4","The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.",[161],[237,238,239],"Gabapentin","Neurorecovery","Feasibility",{"date":196,"type":33},{"date":242,"type":33},"2022-03-14",{"date":244,"type":19},"2026-08-31",{"name":39,"class":40},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":15,"minAge":254,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":20,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":270},"100545913","positive-peers-intervention-clinical-trial-100545913","NCT06388109","Positive Peers Intervention Clinical Trial","Randomized Control Trial of Positive Peers mHealth App as a Clinic-based Intervention to Optimize HIV Outcomes Among Young, Minority Persons Living With HIV","PoPIT","Inclusion Criteria:\n\n* HIV+\n* Identifies as either a racial, ethnic, sexual or gender minority\n\nOne of the following:\n\n* Newly diagnosed within last 12 months\n* Out of care (greater than 6 months between any two HIV provider visits in last 24 months)\n* Not virally suppressed (any viral load \\> 200 copies in last 24 months)\n* Has a working smartphone\n* Functional English ability\n\nExclusion Criteria:\n\n* prior use of Positive Peers mobile app","13 Years","34 Years",{"count":257,"type":19},250,[22],"The goal of this clinical trial is to learn if the Positive Peers mobile app intervention increases rates of viral suppression in young (13-34 y\u002Fo) persons with HIV.\n\nDoes use of the Positive Peers app improve viral suppression among young minority persons with HIV? What user characteristics are associated with a) viral suppression, b) retention in care, and c) perceived HIV-related stigma?\n\nParticipants will:\n\n* download the mobile app onto their personal smartphone\n* Use the mobile app as they find useful\n* complete online surveys at enrollment, 3 mo, 6, mo, 9 mo and 12 months.",[261],"HIV Infections","2025-10-13",{"date":264,"type":33},"2025-10-15",{"date":266,"type":33},"2024-06-03",{"date":268,"type":19},"2027-11",{"name":39,"class":40},6,{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":15,"minAge":278,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":20,"phases":282,"briefSummary":283,"conditions":284,"keywords":288,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":71},"100505793","tdcs--ccfes-mediated-functional-task-practice-for-post-stroke-upper-extremity-hemiplegia-100505793","NCT05866003","tDCS + CCFES-mediated Functional Task Practice for Post-stroke Upper Extremity Hemiplegia","tDCS During Contralaterally Controlled FES for Upper Extremity Hemiplegia","Inclusion Criteria:\n\n1. Age ≥ 21 and ≤ 90\n2. ≥ 6 and ≤ 24 months since first clinical hemorrhagic or nonhemorrhagic stroke\n3. Able to follow 3-stage command\n4. Able to remember 2 of 3 items after 30 minutes\n5. Full volitional elbow extension\u002Fflexion and hand opening\u002Fclosing of unaffected limb\n6. Adequate active movement of shoulder and elbow to position the paretic hand in the workspace for table-top task practice\n7. Patient must be able to sit unassisted in an armless straight-back chair for the duration of the screening portion of the eligibility assessment\n8. Medically stable\n9. ≥ 10° finger and wrist extension\n10. Skin intact on hemiparetic arm, hand and scalp\n11. Muscle contraction can be elicited with Transcranial Magnetic Stimulation\n12. Unilateral upper limb hemiparesis with finger extensor strength of ≤ grade 4\u002F5 on the Medical Research Council (MRC) scale\n13. Score of ≥1\u002F14 and ≤ 11\u002F14 on the hand section of the upper extremity Fugl-Meyer Assessment\n14. While relaxed, surface NMES of finger extensors and thumb extensors and\u002For abductors produces a functional degree of hand opening without pain.\n\nExclusion Criteria:\n\n1. Co-existing neurological condition other than prior stroke involving the hemiparetic upper limb (e.g., peripheral nerve injury, PD, SCI, TBI, MS).\n2. Uncontrolled seizure disorder\n3. Use of seizure lowering threshold medications and the discretion of the study physician\n4. Cardiac pacemaker or other implanted electronic device\n5. Pregnant\n6. IM Botox injections in any UE muscle in the last 3 months\n7. Insensate arm, forearm, or hand\n8. Deficits in communication that interfere with reasonable study participation\n9. Severely impaired cognition and communication\n10. Uncompensated hemi-neglect (extinguishing to double simultaneous stimulation)\n11. Severe shoulder or hand pain (unable to position hand in the workspace without pain)","21 Years","90 Years",{"count":281,"type":19},63,[22],"After a stroke, it is very common to lose the ability to open the affected hand. Occupational and physical rehabilitation therapy (OT and PT) combined with non-invasive brain stimulation may help a person recover hand movement.\n\nThe purpose of this study is to compare 3 non-invasive brain stimulation protocols combined with therapy to see if they result in different amounts of recovery of hand movement after a stroke.",[285,286,287],"Stroke","Upper Extremity Paresis","Hemiplegia",[285,289,290,291,292,293,294,295,296,297,298,299,300],"Rehabilitation","Therapy","Electrical Stimulation","Brain stimulation","Hand","CCFES","Motor Cortex","TMS","Motor Recovery","Central Nervous System","CVA","Upper Limb","2025-09-23",{"date":303,"type":33},"2025-09-29",{"date":305,"type":33},"2023-07-01",{"date":307,"type":19},"2028-04",{"name":39,"class":40},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":15,"minAge":278,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":20,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":71},"100351567","improving-stroke-motor-control-with-non-invasive-brain-stimulation-and-functional-electrical-stimulation-100351567","NCT03857529","Improving Stroke Motor Control With Non-invasive Brain Stimulation and Functional Electrical Stimulation","Contralaterally Controlled FES Plus Transcranial Direct Current Stimulation for Hand Motor Control After Stroke: A Pilot Study","Inclusion Criteria:\n\n1. Age ≥ 21\n2. ≥ 6 months since first clinical hemorrhagic or nonhemorrhagic stroke\n3. Able to follow 3-stage commands and remember 2 of 3 items after 30 minutes\n4. Full volitional elbow extension\u002Fflexion and hand opening\u002Fclosing of unaffected limb\n5. Adequate active movement of shoulder and elbow to position the paretic hand in the workspace for table-top task practice\n6. Patient must be able to sit unassisted in an armless straight-back chair for the duration of the screening portion of the eligibility assessment\n7. Medically stable\n8. ≥ 10° finger extension\n9. Unilateral upper limb hemiparesis with finger extensor strength of ≤ grade 4\u002F5 on the manual muscle test AND a score of\n\n   ≥1 and ≤ 11\u002F14 on the hand section of the upper extremity Fugl-Meyer Assessment\n10. Skin intact on hemiparetic arm, hand and scalp\n11. While relaxed, surface neuromuscular electrical stimulation of finger extensors and thumb extensors and\u002For abductors produces a functional degree of hand opening without pain.\n12. No significant visual or hearing impairment\n\nExclusion Criteria:\n\n1. Co-existing neurological condition other than prior stroke involving the hemiparetic upper limb (e.g., peripheral nerve injury, Parkinson's disease, spinal cord injury, traumatic brain injury, multiple sclerosis).\n2. Uncontrolled seizure disorder\n3. Use of seizure lowering threshold medications at the discretion of the study physician (Dr. Rich Wilson)\n4. Cardiac pacemaker or other implanted electronic device and\u002For stent\n5. Pregnant\n6. Intramuscular botox injections in any upper extremity muscle in the last 3 months\n7. Insensate arm, forearm, or hand\n8. Severely impaired cognition and communication\n9. Uncompensated hemi-neglect (extinguishing to double simultaneous stimulation)\n10. Severe shoulder or hand pain (unable to position hand in the workspace without pain)\n11. Metal implant in the head",{"count":5,"type":19},[22],"This pilot study for stroke patients with chronic upper limb hemiplegia will examine the effects of non-invasive brain stimulation and neuromuscular electrical stimulation on hand motor control and corticospinal excitability. Specifically, this study will investigate the effects of timing and delivery of tDCS in conjunction with contralaterally controlled functional electrical stimulation.",[285,289,293],{"date":303,"type":33},{"date":322,"type":33},"2019-08-01",{"date":324,"type":19},"2028-08-01",{"name":39,"class":40},{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":333,"minAge":334,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":20,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100567185","ultrahypofractionated-whole-breast-radiation-following-chemotherapy-100567185","NCT06664892","Ultrahypofractionated Whole Breast Radiation Following Chemotherapy","Ultrahypofractionated Whole Breast Radiation Following Breast Conserving Surgery and Chemotherapy in Patients > 60 Years of Age With Clinically Low-Risk, Node-Negative Breast Cancer Who Have Received Prior Chemotherapy","Inclusion Criteria:\n\n1. Patients aged at least 60 years with invasive BC (T1-3) with clinically or pathologically negative axillary nodes following BCS who have a high-risk Mammaprint or Oncotype testing and receive chemotherapy. (If no axillary surgery planned, patients must have pre-operative negative axillary ultrasound)\n2. Invasive ductal, lobular, medullary, papillary, colloid (mucinous), or tubular histologies are allowed\n3. Any receptor status is allowed (ER\u002FPR\u002FHer2-neu)\n4. Patients with negative resection margins defined as 2 mm from ink, or a negative re-excision\n5. Bilateral BC is allowed, provided each cancer meets inclusion criteria\n6. Nodal RT is not allowed\n7. There must be no concern for distant metastatic disease\n8. Neoadjuvant or adjuvant chemotherapy is permitted provided pretreatment clinical and radiographic staging meets inclusion criteria. Specific adjuvant\u002Fneoadjuvant therapies are at the discretion of the treating Medical Oncologist. There are no systemic therapies that are not allowed on this study.\n9. Patients must be deemed fit to receive the prescribed systemic therapy\n10. Immunotherapy is allowed\n11. Targeted Her-2 neu therapy, including concurrent therapy is allowed\n12. Other targeted therapies are allowed (including but not limited to CDK inhibitors)\n13. Endocrine therapy, including concurrent therapy is allowed\n14. Participation in other non-RT clinical trial is allowed\n15. Must be able to sign informed consent\n\nExclusion Criteria:\n\n1. Patients with stage IV BC\n2. Surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation. (If surgical margins are rendered free of disease by re-excision, the patient is eligible)\n3. Prior thoracic or breast RT\n4. The following RT methods and techniques are not permitted:\n\n   * Brachytherapy or intraoperative RT (IORT)\n   * Proton therapy\n   * Regional nodal RT\n   * Tumor bed boost\n5. Patients who have breast reconstruction with implant or expander\n6. Patients who have had a mastectomy for current BC\n7. Patients requiring a tumor bed boost\n8. Palpable or radiographic suspicious or contralateral lymph nodes or N2 disease\n9. Paget's disease of the nipple.\n10. Non-epithelial breast malignancies such as sarcoma or lymphoma\n11. History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to study entry\n12. Active collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active skin rash, systemic lupus erythematosis, or scleroderma\n13. Pregnancy or lactation at the time of study entry\u002F or intention to become pregnant during treatment.\n14. Patients with serious medical illness or psychiatric illness that would interfere with the trial.\n15. Patients with active infection in the radiation treatment portal.","FEMALE","60 Years","100 Years",{"count":337,"type":19},213,[22],"This is a single institution, non-randomized, non-inferiority study comparing prospectively collected data for acute and late effects on the breast associated with ultrahypofractionated whole breast radiation (WBI) following breast conserving surgery (BCS) and chemotherapy to historical controls for breast cancer (BC) patients who receive hypofractionated RT following BCS and chemotherapy.",[341],"Breast Cancer","2025-03-13",{"date":344,"type":33},"2025-03-14",{"date":346,"type":19},"2025-04-01",{"date":348,"type":19},"2029-12-31",{"name":39,"class":40},{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":15,"minAge":358,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":20,"phases":361,"briefSummary":363,"conditions":364,"keywords":367,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":375,"leadSponsor":377,"locationsCount":4},"100576707","phase-2-effectiveness-of-a-wearable-hydration-device-100576707","NCT06788795","Effectiveness of a Wearable Hydration Device","Clinical Effectiveness of a Wearable Hydration Device","DRINK","Inclusion Criteria:\n\n* adult patients aged 55 and over\n* rresenting to the emergency department\n* clinical suspicion of dehydration\n* treatment of dehydration\u002Fsyncope with fluid resuscitation\n* English speaking\n\nExclusion Criteria:\n\n* Refusal or inability to give informed consent,\n* severe clinical symptom requiring escalation of care beyond fluid resuscitation (ex. vasopressors, invasive blood pressure monitoring)\n* presumed\u002Fconfirmed diagnosis of syncope secondary to a non-dehydration cause (ex. arrhythmia, stroke, pulmonary embolism, sepsis, valvular heart disease)\n* inability to lay flat for the test\n* body weight greater than 350 lbs\n* inability to fit measurement devices around the participant wrist\n* abnormal bodily fluid retention (lymphedema, ascites, pleural effusions, peripheral edema)\n* neuromotor disorders\n* current congestive heart failure exacerbation or heart attack\u002Fmyocardial infarction\n* any implantable electronic devices\n* skin on limbs in poor condition (excessively, dry or rough or abrasions or wounds that would preclude application of electrode adhesive)","55 Years",{"count":360,"type":19},150,[362],"PHASE2","Dehydration among older adults a costs billions of dollars in US healthcare every year because no robust solution exists to detect changes in hydration and prevent negative outcomes. In this project, TritonX Technologies Inc. and academic research partners plan to test whether a newly created wearable sensor that measures hydration in real time can promote hydration and prevent the dehydration illnesses.\n\nThe investigators will conduct a randomized controlled trial to examine the effectiveness of continuous home monitoring of fluid levels in a cohort of vulnerable older adult patients seen in the emergency care setting.\n\nThe goal of this randomized control trial is to examine the effectiveness of continuous home monitoring of fluid levels in older patients presenting to the emergency department for dehydration. The main questions it aims to answer:\n\n1. Can a wearable device accurately determine the severity of dehydration at home and\n2. can a wearable device and continuous feedback from the device change behavior in the outpatient setting that can lead to improved outcomes in the treatment of dehydration in the elderly?\n\nInvestigators will compare device readings, hydration diaries, vital signs, blood samples, return visits to the emergency department, and to see if feedback from the device decreases signs and symptoms of dehydration and changes home management of dehydration.\n\nParticipants will be asked to:\n\n* wear the device and monitor hydration status\n* record the amount of home hydration\n* return in 7-10 days for reassessment of dehydration\n\nThe successful outcome of this study will include evidence for the effectiveness of the home, wearable hydration monitoring device, data necessary for the FDA 510(k) and related regulatory processes and substantial enhancements to both our knowledge of older adult needs and device functionality.",[365,366],"Dehydration","Syncope and Collapse",[368,369,370,371],"dehydration","total body water","bioimpedence","emergency department","2025-03-10",{"date":342,"type":33},{"date":346,"type":19},{"date":376,"type":19},"2026-12-31",{"name":39,"class":40},{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":387,"phases":4,"briefSummary":388,"conditions":389,"keywords":391,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":403,"locationsCount":4},"100564918","the-expand-study-pharmacist-administered-long-acting-cabotegravir--rilpivirine-to-expand-access-for-people-with-hiv-100564918","NCT06635421","The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIV","EXPAND","Patient Participant Inclusion Criteria:\n\n* 18 years of age and older\n* diagnosed with HIV by approved HIV screen and confirmation test\n* currently on CAB+RPV LA every 4 or 8 weeks\n* has received at least two doses of CAB+PRV LA\n* last HIV-1 RNA \\\u003C50 copies\u002Fml\n* no known or suspected resistance to either cabotegravir or rilpivirine\n* no plans to change medication in the next 48 weeks\n* no plans to move out of state\n* has plans to avoid pregnancy if of reproductive potential\n\nPatient Participant Exclusion Criteria:\n\n* individuals who are unable or unwilling to adhere to the study protocol\n* unable to speak\u002Fcomprehend English\n* insurance coverage for medication through medical benefit\n\nStaff Participant Inclusion\u002FExclusion Criteria:\n\n-all available staff involved in the CAB+RPV LA workflow will be approached for inclusion",{"count":386,"type":19},164,"OBSERVATIONAL","The purpose of The EXPAND study is to develop and pilot a pharmacist led model of medication delivery. Following a co-design phase, patients may receive injections at satellite pharmacies by a licensed pharmacist. The acceptability, appropriateness, and feasibility of this approach and standard in clinic administration by a nurse will be assessed.",[390],"HIV I Infection",[392,393,394,395,396],"long acting injectable antiretroviral therapy","cabotegravir","rilpivirine","HIV","pharmacist administered medication","2024-10-08",{"date":399,"type":33},"2024-10-10",{"date":401,"type":19},"2024-11-01",{"date":376,"type":19},{"name":39,"class":40},""]